伊立替康
医学
紫杉醇
顺铂
肿瘤科
联合疗法
环磷酰胺
药理学
内科学
前列腺癌
化疗
联合化疗
喜树碱
结直肠癌
癌症
化学
有机化学
作者
William R. Waud,Karen S. Gilbert,John A. Secrist
标识
DOI:10.1080/15257770.2012.712181
摘要
Thiarabine is undergoing clinical trials. In support of that effort combination therapy of thiarabine plus six clinical anticancer agents was evaluated using various human tumor xenograft models. The antitumor activity of thiarabine in combination appeared to be greater than additive with irinotecan (DLD-1 colon), paclitaxel (PC-3 prostate), cisplatin (PC-3 prostate), or cyclophosphamide (RL lymphoma), additive with irinotecan (NCI-H460 NSCLC), cisplatin (NCI-H460 NSCLC) or methotrexate (CCRF-CEM leukemia), and less than additive with irinotecan (HT29 colon), paclitaxel (NCI-H460 NSCLC) or cisplatin (NCI-H23 NSCLC). Combining thiarabine with irinotecan, paclitaxel, cisplatin, or cyclophosphamide should receive consideration in the clinical treatment of cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI